KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, and Amanda Hodges, director of implementation for ReVital Cancer Rehabilitation, who acts as a bridge between the oncology world and the rehabilitation world, discuss overcoming barriers in practices to help patients with cancer get the rehab care they need, how patients with cancer can benefit from rehab, and defining value.

Related Videos

Related Content

Advertisement

April 2nd 2025

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

Hayden E. Klein

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

April 2nd 2025

Prior Authorizations and the Adverse Impact on Continuity of Care

Jay S. Pickern, DBA

Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

March 31st 2025

Enhancing Quality in Virtual Care Delivery

Maggie L. Shaw

Strategies to enhance virtual care through quality assurance frameworks, technological innovation, and provider support were laid out in a pair of posters presented at the recent AMGA Annual Conference.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

Related Content

Advertisement

April 2nd 2025

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

Hayden E. Klein

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

April 2nd 2025

Prior Authorizations and the Adverse Impact on Continuity of Care

Jay S. Pickern, DBA

Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

March 31st 2025

Enhancing Quality in Virtual Care Delivery

Maggie L. Shaw

Strategies to enhance virtual care through quality assurance frameworks, technological innovation, and provider support were laid out in a pair of posters presented at the recent AMGA Annual Conference.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.